Current Edition

Centralised ECGs Help Ensure Cardiac Safety of Obesity Drugs

Obesity rates have dramatically increased over the past 20 years, making it one of the most prevalent health problems in the world. Despite this, there are only a very small number of adequately safe and effective obesity drugs available on the market to treat the condition. Robert Kleiman at ERT discusses how centralised ECG trials have emerged as a viable method for helping drug companies provide reliable cardiovascular data in their attempts to achieve regulatory compliance, while also benefiting from significantly improved data accuracy and reliability, time and cost savings, and access to breakthrough technologies.
 
[prettyfilelink src=”http://ipimediaworld.com/wp-content/uploads/2012/09/Pages-from-IPI-Volume4Issue3-46.pdf” type=”pdf”]Pages from IPI-Volume4Issue3-4[/prettyfilelink]
 
http://ipimediaworld.com/wp-content/uploads/2012/09/Pages-from-IPI-Volume4Issue3-42.pdf